ErbB2 (HER-2) Monoclonal Antibody (e2-4001), Biotin | Invitrogen MA5-13102 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

ErbB2 (HER-2) Monoclonal Antibody (e2-4001), Biotin

catalog :

MA5-13102

quantity :

500 µL

price :

US 500

clonality :

monoclonal

host :

mouse

conjugate :

biotin

clone name :

e2-4001

reactivity :

hamsters, human, mouse, rat, cat

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry

citations: 100

Published Application/Species/Sample/Dilution	Reference
immunoprecipitation; human; fig 3D western blot; human; fig 3D	Hu S, Sun Y, Meng Y, Wang X, Yang W, Fu W, et al. Molecular architecture of the ErbB2 extracellular domain homodimer. Oncotarget. 2015;6:1695-706 pubmed
immunohistochemistry; human; 1:300	Zhang Q, Ming J, Zhang S, Li B, Yin L, Qiu X. Micropapillary component in gastric adenocarcinoma: an aggressive variant associated with poor prognosis. Gastric Cancer. 2015;18:93-9 pubmed publisher
immunocytochemistry; human immunohistochemistry; human	Fichter C, Timme S, Braun J, Gudernatsch V, Schöpflin A, Bogatyreva L, et al. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. Int J Cancer. 2014;135:1517-30 pubmed publisher
immunoprecipitation; human	Steinkamp M, Low Nam S, Yang S, Lidke K, Lidke D, Wilson B. erbB3 is an active tyrosine kinase capable of homo- and heterointeractions. Mol Cell Biol. 2014;34:965-77 pubmed publisher
immunohistochemistry; human; 1:3000	Falchook G, Moulder S, Wheler J, Jiang Y, Bastida C, Kurzrock R. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann Oncol. 2013;24:3004-11 pubmed publisher
western blot; human	Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, et al. A cell-based screening system for influenza A viral RNA transcription/replication inhibitors. Sci Rep. 2013;3:1106 pubmed publisher
immunohistochemistry; human	Hechtman J, Polydorides A. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med. 2012;136:691-7 pubmed publisher
immunoprecipitation; human	Li X, Kuang J, Shen Y, Majer M, Nelson C, Parsawar K, et al. The atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cells. J Biol Chem. 2012;287:23171-83 pubmed publisher
immunohistochemistry; human	Xu J, Wan M, He Q, Bassett R, Fu X, Chen A, et al. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat. 2012;134:531-41 pubmed publisher
immunohistochemistry; human	Kelly C, Bernard P, Krishnamurthy S, Wang B, Ebbert M, Bastien R, et al. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer. Oncologist. 2012;17:492-8 pubmed publisher
western blot; human	Manandhar S, Choi B, Jung K, Ryoo I, Song M, Kang S, et al. NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity. Free Radic Biol Med. 2012;52:1773-85 pubmed publisher
immunohistochemistry; human; 1:400	Yigit S, Pehlivan F, Evcim G, Etit D. Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases. Pathol Res Pract. 2012;208:147-50 pubmed publisher
immunohistochemistry; human; 1:200	El Gendi S, Mostafa M, El Gendi A. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res. 2012;18:459-69 pubmed publisher
immunohistochemistry; human	Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy B, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol. 2012;23:1144-50 pubmed publisher
immunoprecipitation; human; 2-5 ug/time	DeFazio Eli L, Strommen K, Dao Pick T, Parry G, Goodman L, Winslow J. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res. 2011;13:R44 pubmed publisher
western blot; human	Fernand V, Losso J, Truax R, Villar E, Bwambok D, Fakayode S, et al. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro. Chem Biol Interact. 2011;192:220-32 pubmed publisher
immunohistochemistry; human; 1:300	Reuben J, Lee B, Gao H, Cohen E, Mego M, Giordano A, et al. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44?CD24lo cancer stem cell phenotype. Eur J Cancer. 2011;47:1527-36 pubmed publisher
immunohistochemistry; human; 1:300	Ege C, Akbulut M, Zekioglu O, Ozdemir N. Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival. Arch Gynecol Obstet. 2011;284:1231-9 pubmed publisher
immunohistochemistry; human; 1:1	Abdelzaher E, El Gendi S, Yehya A, Gowil A. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br J Neurosurg. 2011;25:707-13 pubmed publisher
immunohistochemistry; human	Kuerer H, Buzdar A, Mittendorf E, Esteva F, Lucci A, Vence L, et al. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011;117:39-47 pubmed publisher
immunoprecipitation; human western blot; human	Bollig Fischer A, Dziubinski M, Boyer A, Haddad R, Giroux C, Ethier S. HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation. Cancer Res. 2010;70:7862-73 pubmed publisher
ELISA; human western blot; human	Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res. 2010;16:4226-35 pubmed publisher
western blot; human	Fisher R, Ultsch M, Lingel A, Schaefer G, Shao L, Birtalan S, et al. Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine. J Mol Biol. 2010;402:217-29 pubmed publisher
immunohistochemistry; human; 1:2000	Rygiel A, Milano F, ten Kate F, Bergman J, Krishnadath K. Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus. J Oncol. 2010;2010:382582 pubmed publisher
immunocytochemistry; human western blot; human	Pfister A, Wood R, Salas P, Zea D, Ramsauer V. Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling. J Cell Biochem. 2010;111:643-52 pubmed publisher
immunohistochemistry; human; 1:300	Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen E, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010;116:3330-7 pubmed publisher
immunohistochemistry; human	Norell H, Poschke I, Charo J, Wei W, Erskine C, Piechocki M, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med. 2010;8:53 pubmed publisher
western blot; human; 1:500	Wang F, Ren J, Qiu X, Wang L, Zhu Q, Zhang Y, et al. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence. Clin Cancer Res. 2010;16:2284-94 pubmed publisher
immunohistochemistry; human; 1:300	Williams M, Roberts D, Kies M, Mao L, Weber R, El Naggar A. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res. 2010;16:2266-74 pubmed publisher
immunohistochemistry; mouse; 1:100	Zheng J, Mercado Uribe I, Rosen D, Chang B, Liu P, Yang G, et al. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle. 2010;9:140-6 pubmed
immunohistochemistry; human; 1:100	Arias Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee S, et al. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res Treat. 2010;123:51-8 pubmed publisher
immunohistochemistry; human; 1:100	Gong Y, Sweet W, Duh Y, Greenfield L, Tarco E, Trivedi S, et al. Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria. Am J Clin Pathol. 2009;132:228-36 pubmed publisher
immunohistochemistry; cat	Misirlioglu D, Nak D, Ozyigit M, Nak Y, Akkoc A. HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats. J Feline Med Surg. 2009;11:885-8 pubmed publisher
western blot; human; 1:1000	Liu X, Wu J, Zhang S, Li C, Huang Q. Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy. Cancer Gene Ther. 2009;16:861-72 pubmed publisher
immunohistochemistry; human; 1:100	Ge Y, Sneige N, Eltorky M, Wang Z, Lin E, Gong Y, et al. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res. 2009;11:R28 pubmed publisher
immunohistochemistry; human; 1:300	Middleton L, Price K, Puig P, Heydon L, Tarco E, Sneige N, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases t. Arch Pathol Lab Med. 2009;133:775-80 pubmed publisher
immunocytochemistry; human; 1:200 western blot; human; 1:800	Ren X, Xu Y, Bao W, Fu H, Wu C, Zhao Y, et al. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. Cancer Lett. 2009;281:134-43 pubmed publisher
immunohistochemistry; human	Gilcrease M, Woodward W, Nicolas M, Corley L, Fuller G, Esteva F, et al. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol. 2009;33:759-67 pubmed publisher
immunocytochemistry; human	Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol. 2009;18:11-21 pubmed publisher
immunocytochemistry; human western blot; human	Pedersen N, Breen K, Rødland M, Haslekås C, Stang E, Madshus I. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2. Mol Cancer Res. 2009;7:275-84 pubmed publisher
immunohistochemistry; human	Dawood S, Broglio K, Kau S, Green M, Giordano S, Meric Bernstam F, et al. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 2009;27:220-6 pubmed publisher
western blot; human; 1:1000	Dilworth J, Wojtkowiak J, Mathieu P, Tainsky M, Reiners J, Mattingly R, et al. Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033. Cancer Biol Ther. 2008;7:1938-46 pubmed
western blot; human	Van Schaeybroeck S, Kelly D, Kyula J, Stokesberry S, Fennell D, Johnston P, et al. Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. Cancer Res. 2008;68:8312-21 pubmed publisher
immunohistochemistry; human; 1:300	Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, et al. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol. 2008;16:530-4 pubmed publisher
western blot; mouse; 1:2.000	Strumane K, Rygiel T, van der Valk M, Collard J. Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice. J Cancer Res Clin Oncol. 2009;135:69-80 pubmed publisher
immunoprecipitation; human western blot; human	Arora P, Cuevas B, Russo A, Johnson G, Trejo J. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene. 2008;27:4434-45 pubmed publisher
western blot; human	Pedersen N, Madshus I, Haslekås C, Stang E. Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent. Mol Cancer Res. 2008;6:491-500 pubmed publisher
immunohistochemistry; human	Dawood S, Broglio K, Gong Y, Yang W, Cristofanilli M, Kau S, et al. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer. 2008;112:1905-11 pubmed publisher
immunoprecipitation; human western blot; human	Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res. 2008;149:9-14 pubmed publisher
western blot; human	Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar V. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res. 2008;68:483-91 pubmed publisher
immunohistochemistry; human; 1:250	Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E. Primary neuroendocrine carcinoma of the breast: a case report. Tumori. 2007;93:496-8 pubmed
western blot; human; 0.1 ug/ml	Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, et al. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins. 2008;70:938-49 pubmed
immunohistochemistry; hamsters; 1:150	Vairaktaris E, Moulavassili P, Loukeri S, Spyridonidou S, Yapijakis C, Vassiliou S, et al. Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis. J Musculoskelet Neuronal Interact. 2007;7:185-90 pubmed
immunohistochemistry; human; 1:100	Andre F, Mazouni C, Liedtke C, Kau S, Frye D, Green M, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat. 2008;108:183-90 pubmed
immunohistochemistry; human; 1:100	Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 2007;8:203-11 pubmed
immunohistochemistry; human	Tokatli F, Alas R, Altaner S, Pala F, Uygun K, Uzal C, et al. [An analysis of genetic transmission in a father and son with osteosarcoma]. Acta Orthop Traumatol Turc. 2006;40:407-10 pubmed
western blot; human	Scroggins B, Robzyk K, Wang D, Marcu M, Tsutsumi S, Beebe K, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell. 2007;25:151-9 pubmed
immunohistochemistry; human; 1:100	Nash J, Barrett T, Kies M, Ross M, Sneige N, Diwan A, et al. Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications. J Cutan Pathol. 2007;34:49-54 pubmed
immunohistochemistry; human; 1:100	Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva F, et al. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer. 2007;109:496-501 pubmed
immunohistochemistry; human; 1:100	Karg A, Dinç Z, Basok O, Ucvet A. MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC). Pathol Res Pract. 2006;202:577-83 pubmed
immunocytochemistry; human western blot; human	Ramsauer V, Pino V, Farooq A, Carothers Carraway C, Salas P, Carraway K. Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2. Mol Biol Cell. 2006;17:2931-41 pubmed
western blot; human; 1:200	Hansen M, Roehm P, Chatterjee P, Green S. Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. Glia. 2006;53:593-600 pubmed
immunohistochemistry; human	Symmans W, Fiterman D, Anderson S, Ayers M, Rouzier R, Dunmire V, et al. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer. 2005;12:1059-69 pubmed
western blot; human; 1:3000	Kassouf W, Dinney C, Brown G, McConkey D, Diehl A, Bar Eli M, et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 2005;65:10524-35 pubmed
western blot; human	Van Schaeybroeck S, Karaiskou McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res. 2005;11:7480-9 pubmed
immunoprecipitation; human; 1 ug/mg	Woods Ignatoski K, Dziubinski M, Ammerman C, Ethier S. Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells. Neoplasia. 2005;7:788-98 pubmed
immunohistochemistry; human; 1:300	Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, O Yildirim E, et al. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis. 2005;22:39-46 pubmed
immunohistochemistry; human; 1:300	Cabioglu N, Yazici M, Arun B, Broglio K, Hortobagyi G, Price J, et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res. 2005;11:5686-93 pubmed
immunohistochemistry; human	Diaz L, Cristofanilli M, Zhou X, Welch K, Smith T, Yang Y, et al. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol. 2005;18:1165-75 pubmed
flow cytometry; human; 0.5 ug/ml western blot; human; 0.5 ug/ml	Chan C, Metz M, Kane S. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat. 2005;91:187-201 pubmed
immunohistochemistry; human	Diaz L, Zhou X, Wright E, Cristofanilli M, Smith T, Yang Y, et al. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res. 2005;11:3309-14 pubmed
immunoprecipitation; human western blot; human	Reed C, Waterhouse A, Kirby S, Kay P, Owens R, McQuillan D, et al. Decorin prevents metastatic spreading of breast cancer. Oncogene. 2005;24:1104-10 pubmed
immunoprecipitation; human western blot; human	Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, Watanabe T, et al. Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells. Biochem Biophys Res Commun. 2005;327:907-14 pubmed
immunohistochemistry; rat; 1:600 western blot; rat	Price Schiavi S, Andrechek E, Idris N, Li P, Rong M, Zhang J, et al. Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy. J Cell Physiol. 2005;203:44-53 pubmed
	Sim xf3 Riudalbas L, Offner S, Planet E, Duc J, Abrami L, Dind S, et al. Transposon-activated POU5F1B promotes colorectal cancer growth and metastasis. Nat Commun. 2022;13:4913 pubmed publisher
	Weinberg F, Han M, Dahmke I, del Campo A, de Jonge N. Anti-correlation of HER2 and focal adhesion complexes in the plasma membrane. PLoS ONE. 2020;15:e0234430 pubmed publisher
	Cianciaruso C, Beltraminelli T, Duval F, Nassiri S, Hamelin R, Mozes A, et al. Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles. Cell Rep. 2019;27:3062-3080.e11 pubmed publisher
	Huang W, REINHOLZ M, Weidler J, Yolanda L, Paquet A, Whitcomb J, et al. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol. 2010;134:303-11 pubmed publisher
	Zhang L, Fletcher Turner A, Marchionni M, Apparsundaram S, Lundgren K, Yurek D, et al. Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures. J Neurochem. 2004;91:1358-68 pubmed
	Wang S, Lien H, Xia W, Chen I, Lo H, Wang Z, et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell. 2004;6:251-61 pubmed
	Gossett D, Alo P, Bristow R, Galati M, Kyshtoobayeva A, Fruehauf J, et al. Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients. Int J Gynecol Cancer. 2004;14:145-51 pubmed
	Cloven N, Kyshtoobayeva A, Burger R, Yu I, Fruehauf J. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol. 2004;92:160-6 pubmed
	Esteva F, Sahin A, Smith T, Yang Y, Pusztai L, Nahta R, et al. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 2004;100:499-506 pubmed
	Esteva F, Sahin A, Rassidakis G, Yuan L, Smith T, Yang Y, et al. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res. 2003;9:5652-9 pubmed
	Yang G, Cai K, Thompson Lanza J, Bast R, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem. 2004;279:4339-45 pubmed
	Middleton L, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer. 2003;98:1055-60 pubmed
	Simpson R, Prasad A, Lewis J, Skalova A, David L. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2003;27:1070-9 pubmed
	Vadlamudi R, Sahin A, Adam L, Wang R, Kumar R. Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett. 2003;543:76-80 pubmed
	Ramsauer V, Carraway C, Salas P, Carraway K. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J Biol Chem. 2003;278:30142-7 pubmed
	Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G, et al. Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. Virchows Arch. 2003;442:322-8 pubmed
	Davis D, Buchholz T, Hess K, Sahin A, Valero V, McConkey D. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res. 2003;9:955-60 pubmed
	Shimizu H, Seiki T, Asada M, Yoshimatsu K, Koyama N. Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells. Oncogene. 2003;22:831-9 pubmed
	Verschraegen C, Hu W, Du Y, Mendoza J, Early J, Deavers M, et al. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res. 2003;9:845-52 pubmed
	Talukder A, Mishra S, Mandal M, Balasenthil S, Mehta S, Sahin A, et al. MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions. J Biol Chem. 2003;278:11676-85 pubmed
	Stoll S, Kansra S, Elder J. Metalloproteinases stimulate ErbB-dependent ERK signaling in human skin organ culture. J Biol Chem. 2002;277:26839-45 pubmed
	Esteva F, Valero V, Booser D, Guerra L, Murray J, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:1800-8 pubmed
	Half E, Tang X, Gwyn K, Sahin A, Wathen K, Sinicrope F. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002;62:1676-81 pubmed
	Lammering G, Lin P, Contessa J, Hampton J, Valerie K, Schmidt Ullrich R. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Int J Radiat Oncol Biol Phys. 2001;51:775-84 pubmed
	Murillo H, Schmidt L, Tindall D. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2. Cancer Res. 2001;61:7408-12 pubmed
	Stoll S, Kansra S, Peshick S, Fry D, Leopold W, Wiesen J, et al. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes. Neoplasia. 2001;3:339-50 pubmed

product information

Product Type :

Antibody

Product Name :

ErbB2 (HER-2) Monoclonal Antibody (e2-4001), Biotin

Catalog # :

MA5-13102

Quantity :

500 µL

Price :

US 500

Clonality :

Monoclonal

Purity :

Protein G

Host :

Mouse

Reactivity :

Human, Mouse, Rat

Applications :

Immunohistochemistry: 1:200-400, Immunoprecipitation: 2 µg/mL, Western Blot: 1-2 µg/mL

Species :

Human, Mouse, Rat

Clone :

e2-4001

Isotype :

IgG1

Storage :

4° C

Description :

Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.

Immunogen :

Cytoplasmic domain of recombinant human c-erbB-2/HER-2 oncoprotein

Format :

Liquid

Applications w/Dilutions :

Immunohistochemistry: 1:200-400, Immunoprecipitation: 2 µg/mL, Western Blot: 1-2 µg/mL

Aliases :

avian erythroblastosis oncogene B 2; Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog); CD antigen CD340; CD340; c-erb B2/neu protein; c-erbB2; C-erbB-2; c-neu; epidermal growth factor receptor-related protein; erbb 2; ERBB2; erb-b2; Erbb-2; ErbB2 (pTyr1139); ErbB2 (pY1139); ErbB2 phospho Y1139; erb-b2 receptor tyrosine kinase 2; her 2; HER2; HER-2; HER-2/neu; herstatin; human epidermal growth factor receptor 2; Kiaa3023; metas; Metastatic lymph node gene 19 protein; mKIAA3023; MLN 19; MLN19; NEU; Neu oncogene; NEU proto-oncogene; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; p185erbB2; p185neu; phospho ErbB2; Proto-oncogene c-ErbB-2; proto-oncogene NEU; Receptor tyrosine-protein kinase erbB-2; TKR1; Tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)